CurrentBlue Cross Blue Shield - OklahomaPolicy CPCPLAB026

Fecal Calprotectin Testing in Adults

Coverage and reimbursement criteria for fecal calprotectin laboratory testing in individuals 18 years of age and older for Blue Cross Blue Shield of Oklahoma.

Policy Summary

PayerBlue Cross Blue Shield - Oklahoma

PolicyFecal Calprotectin Testing in Adults

Policy CodePolicy CPCPLAB026

Change TypeAdult‑only applicability addedwording clarifications

Effective DateOct 30, 2024

Next Review Date

Key ActionConfirm member plan documents for product‑specific coverage and submit accurate documentation and CPT 83993 when applicable.

SourceLink

POLICY UPDATE CHANGES

Added a note indicating this policy is specific to individuals 18 years of age or older; criteria do not apply to individuals less than 18 years of age.

Reimbursement statements revised to remove leading phrases and clarify applicability to adult individuals 18 years and older.

18+Age of applicability

3Reimbursable scenarios

1CPT code listed

CPCPLAB026Policy identifier

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Medically Necessary / Reimbursable Indications

Covered when any of the following adult indications apply:

Covered indications: 1) Differential diagnosis between non-inflammatory gastrointestinal disease (e.g., IBS) and inflammatory gastrointestinal disease (e.g., IBD).adults 18+

Policy applies only to individuals 18 years of age or older.

Covered indications: 2) Fecal calprotectin testing to assess response to therapy, detect relapse, or monitor gastrointestinal conditions such as inflammatory bowel disease (IBD).adults 18+

Policy applies only to individuals 18 years of age or older.

Not Reimbursable Indications

Not covered when:

Not reimbursable: Fecal calprotectin testing for all other situations not discussed above is not reimbursable.adults 18+

Applies only to adults per policy.

Fecal calprotectin testing is covered when used in adults (age 18 and older) for specific clinical indications. Covered indications include: 1) helping to differentiate non-inflammatory gastrointestinal conditions (e.g., IBS) from inflammatory gastrointestinal disease (e.g., IBD), and 2) assessing response to therapy, detecting relapse, or monitoring known inflammatory bowel disease (IBD). This policy applies only to individuals 18 years of age or older.

All other clinical situations not specifically listed as reimbursable above are considered not medically necessary and are not covered under this policy. Providers should confirm that the testing indication matches one of the covered clinical purposes before submitting claims.

Not Covered

Testing performed for indications other than the specified diagnostic differentiation between non-inflammatory and inflammatory gastrointestinal disease or for IBD monitoring/assessment of therapy response or relapse (as described in this policy) is not reimbursable.

Procedure Codes

Procedure CodesCPT

83993

Calprotectin; fecal

Provider Actions and Billing Notes

Documentation Required

Policy and Documentation Governance

If a conflict exists between this Clinical Payment and Coding Policy and a member's plan documents, the plan documents will govern. Similarly, provider contracts supersede this policy where applicable. Providers must use reasonable discretion and may be asked to supply additional documentation upon request.

Plan documents include Certificates of Health Care Benefits, benefit booklets, Summary Plan Descriptions, and other coverage documents.
BCBSOK has discretionary authority to interpret and apply this policy to services delivered in particular cases.

Documentation Required

Documentation and Coding Requirements

Providers are responsible for submission of accurate documentation and coding. Claims must be submitted using valid HIPAA-approved code sets and follow industry-standard coding guidelines. Claims may be reviewed and denied if documentation or coding does not meet plan, contract, or policy requirements.

Follow Uniform Billing Editor, AMA CPT, HCPCS, ICD-10-CM/PCS, NDC, DRG, CMS NCCI and related guidance.
Upon request, submit supporting documentation to substantiate medical necessity and coding.

Note

Coverage Varies by Product and Plan

BCBSOK has implemented lab management reimbursement criteria that vary by product and plan. Review the member's plan documents and benefits to determine whether fecal calprotectin testing is covered for the specific product.

Not all requirements apply to every product — check plan-specific coverage.
Code applicability (e.g., 83993) may depend on the member's product and benefit design.

Denial Risk

Reimbursement Scope and Unsupported Indications

This policy applies only to adults (individuals 18 years of age or older). Reimbursement criteria: (1) fecal calprotectin testing for differential diagnosis between non-inflammatory and inflammatory gastrointestinal disease may be reimbursable; (2) testing to assess response to therapy, relapse, or to monitor IBD may be reimbursable; (3) testing for other situations is not reimbursable. Claims for indications outside the allowed uses may be denied.

Policy is specific to individuals >=18 years of age.
Unsupported indications or uses not described in the reimbursement information may be denied.

Denial Risk

Denial Risk for Incomplete Documentation/Coding

Claims not meeting plan or coding guidelines, or lacking required documentation, may be denied. Submit accurate codes and full clinical documentation to avoid delays or denials.

Claims are subject to code edit protocols and claim review, including benefit terms, provider contract language, and medical/clinical payment policies.
Providers are urged to submit additional documentation upon request.

Ordering Requirements

Step Therapy

Ordering requirements — verify plan‑specific rules

Check the member's plan documents because not all lab management reimbursement requirements apply to every product; confirm eligibility and any product‑specific ordering or coverage rules before ordering testing.

Review Certificates of Benefits, benefit booklets, and Summary Plan Descriptions for coverage details.
BCBSOK may use discretion when interpreting and applying this policy to a specific case.

Frequency Limits

Frequency limits

Plan-specific applicabilityNot all requirements apply to each product; providers must review plan documents for eligible coverage.

Frequency limit detailNo numerical frequency limits specified in policy; frequency is determined by clinical need and plan-specific rules.

Age restrictionPolicy applies only to individuals 18 years of age and older.

Prior authorization / coverage dependenceReimbursement criteria apply and coverage may vary by product — verify eligibility before ordering.

Definitions

Fecal calprotectin testing (definition and uses)

DefinitionMeasurement of fecal calprotectin as a biomarker for intestinal inflammation used to differentiate inflammatory versus non-inflammatory GI disease and to monitor IBD.

Typical clinical usesDifferential diagnosis between non-inflammatory GI disease (e.g., IBS) and inflammatory GI disease (e.g., IBD); assessing response to therapy; detecting relapse; monitoring IBD.

Age applicabilityThis testing policy is specific to individuals 18 years of age or older.

Supporting evidenceClinical literature and guideline references cited (examples include Burri & Beglinger 2014; Campbell et al. 2021).

Background

Fecal calprotectin is a noninvasive biomarker measured in stool that reflects intestinal inflammation. It is used clinically to help distinguish inflammatory bowel disease from non-inflammatory disorders (such as irritable bowel syndrome), and to support assessment of treatment response, detection of relapse, and routine monitoring in patients with established IBD. This policy is limited to adults 18 years of age and older.